ST诺泰上市首年就进行业绩造假，还涉及欺诈发行，ST诺泰五年内不得申请再融资

Group 1 - The core issue involves ST Nuotai engaging in financial fraud during its first year of listing on the STAR Market, which included falsifying performance reports to secure refinancing of 434 million yuan [1] - The company received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) and disciplinary action from the Shanghai Stock Exchange [1] - ST Nuotai specializes in the independent research and development of peptide drugs and small molecule chemical drugs, having been listed on the STAR Market since May 20, 2021 [1] Group 2 - ST Nuotai was previously a highly popular stock in the A-share market, particularly known for its weight-loss drug concept [1] - The company is now prohibited from applying for refinancing for five years due to its fraudulent activities [1]